Evolus Inc (EOLS): Mizuho Securities Keeps Buy Rating Today, Has a Target of $16.0000/Share

May 17, 2018 - By Mona Holcomb

Evolus Inc (EOLS) Rating Reaffirmed

They currently have a $16.0000 target price per share on Evolus Inc (EOLS). The target price by Mizuho Securities would suggest a potential upside of 23.65 % from the company’s previous stock close. This has been shown in analysts report on 16 May.

Evolus, Inc. (NASDAQ:EOLS) Ratings Coverage

Among 2 analysts covering Evolus Inc (EOLS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Evolus Inc has $25.0 highest and $2100 lowest target. $23’s average target is 77.74% above currents $12.94 stock price. Evolus Inc had 7 analyst reports since March 5, 2018 according to SRatingsIntel. On Thursday, April 19 the stock rating was maintained by Mizuho with “Buy”. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, April 12. On Monday, March 5 the stock rating was initiated by Cantor Fitzgerald with “Buy”. Mizuho initiated it with “Buy” rating and $21.0 target in Monday, March 5 report. Mizuho maintained Evolus, Inc. (NASDAQ:EOLS) on Monday, May 7 with “Buy” rating. Cantor Fitzgerald maintained Evolus, Inc. (NASDAQ:EOLS) rating on Tuesday, April 3. Cantor Fitzgerald has “Buy” rating and $2500 target.

The stock increased 20.93% or $2.24 during the last trading session, reaching $12.94. About 668,850 shares traded or 221.59% up from the average. Evolus, Inc. (EOLS) has 0.00% since May 18, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts await Evolus, Inc. (NASDAQ:EOLS) to report earnings on August, 9. After $-0.30 actual earnings per share reported by Evolus, Inc. for the previous quarter, Wall Street now forecasts 36.67 % negative EPS growth.

Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. The company has market cap of $305.91 million. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. It currently has negative earnings.

More notable recent Evolus, Inc. (NASDAQ:EOLS) news were published by: Seekingalpha.com which released: “Evolus: Is The Botox Knock Off Finally Here?” on May 14, 2018, also Benzinga.com with their article: “Benzinga Pro’s 5 Stocks To Watch Today” published on May 16, 2018, Globenewswire.com published: “Evolus Announces Progress with DWP-450 Regulatory Submissions” on May 16, 2018. More interesting news about Evolus, Inc. (NASDAQ:EOLS) were released by: Seekingalpha.com and their article: “Botox Knock Off Could Change Fortunes For Evolus” published on May 17, 2018 as well as Nasdaq.com‘s news article titled: “Mid-Afternoon Market Update: Blink Charging Rises After Q1 Results; Purple Innovation Shares Slide” with publication date: May 16, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: